Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

131.46 -1.08 (-0.82%)
Streaming Delayed Price Updated: 1:06 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Bioscienc

< Previous 1 2 3 4 5 6 7 Next >
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind
DexCom, Blackstone and Royal Caribbean head this list of five stocks. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
NASDAQ:NBIX is not too expensive for the growth it is showing.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX.
Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base
Three of the featured stocks are closing in on record highs. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying.
When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock?
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. 
Via InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced.
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. 
Via Chartmill
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Earnings Outlook For Neurocrine Biosciences
Via Benzinga
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. 
Via Investor's Business Daily
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. 
Via Benzinga
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.